Novartis to discuss considerations and critical success factors in ADC development

SMi reports (09.02.2016, London UK): Specialists from Novartis to speak on ADC development at the 5th ADC Summit in London.
By: SMi Group
 
 
5th ADC Summit
5th ADC Summit
LONDON - Feb. 10, 2016 - PRLog -- Lead specialists from Novartis are set to discuss challenges and lessons learnt from recent developments of antibody drug conjugates at the 5th ADC Summit in London on 23 – 24 May 2016. The two-day event provides a comprehensive analysis of the various approaches with the next generation ADCs led by industry experts including Roche, Takeda, Pfizer, AstraZeneca, Bayer and more. For more details, visit https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit?utm_medium=www.adcsummit.com&utm_source=P-172&utm_campaign=prlog.

Jens Lohrmann, Senior Global Program Manager for Translational Clinical Oncology will be presenting about the challenges and lessons learnt in ADC CMC development and outsourcing. He will cover the following topics:

• Buy vs make: considerations and critical success factors
• Scale-up and site transfer of a conjugation process with impact on key product quality attributes
• Analytical transfers: considerations and lessons from a challenging assay transfers.

Carl Uli Bialucha, Senior Investigator I for Oncology Biotherapeutics, will present about “Targeting Cadherin-6 with a novel ADC for the treatment of ovarian and renal cancers”. His session will discuss

• ADC lead selection covering optimal choice of antibody and linker/payload
• PK/PD studies to evaluate MoA and projected efficacious dose
• Population-scale in vivo assessment in ovarian cancer PTX clinical trial.

Other key presentations include:

• ADCETRIS developed to treat Hodgkin Lymphoma
Ashish Gautam, Global Medical Lead – ADCETRIS, Takeda

• Predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies
Ben-Fillippo Krippendeorff, Principal Scientist, Roche

• Impact of drug loading on ADC target binding and cytotoxicity
Debbie Meyer, Senior Principal Scientist, Pfizer

• The design, synthesis and scale-up of an ADC tubulysin
Jeremy Parker, Principal Scientist, Pharmaceutical Development, AstraZeneca and many more.

The full speaker lineup can be found on https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summi....

In addition to the conference, the event will feature two exclusive half-day post-conference workshops held on the 25 May 2016:

1. ADC payloads: Availability and mechanisms of action
Hosted by Femtogenix and King’s Cross London

2. Developments in high potency API manufacturing
Hosted by SKAN AG

For more information or to register visit the event website at https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit?utm_medium=www.adcsummit.com&utm_source=P-172&utm_campaign=prlog.

There is an early bird discount of £400 for bookings before 29 February.

For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

For delegate bookings contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

For media enquiries contact Honey de Gracia on +44 (0) 20 7827 6102 or email hdegracia@smi-online.co.uk

5th ADC Summit
23-24 May 2016 | London, UK
Contact e-mail: hdegracia@smi-online.co.uk
Event Website: https://www.smi-online.co.uk/pharmaceuticals/uk/adc-summit?utm_medium=www.adcsummit.com&utm_source=P-172&utm_campaign=prlog

Contact
Honey de Gracia
***@smi-online.co.uk
End
Source:SMi Group
Email:***@smi-online.co.uk
Posted By:***@smi-online.co.uk Email Verified
Tags:Antibody Drug Conjugates, Oncology, Pharmaceutical Updates
Industry:Medical
Location:London City - London, Greater - England
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share